As reported on Drugs, BioNTech has decided to halt development of its Phase 2 BNT122-01 study investigating autogene cevumeran (BNT122/RO7198457) in patients with resected colorectal cancer who remained ctDNA-positive after…
Today the Tin Soldier Disease has a treatment. A clinical trial showed a 90% reduction in new bone development in adults with FOP. After Decades of Hope Deferred, Pasatru Offers…
Historic Milestone Offers Relief from Relentless Burden of Glycogen Storage Disease Type Ia According to a recent press release from Ultragenyx, after decades of medical innovation and tireless advocacy from…
What Happened? Hansa Biopharma, a Swedish company, announced that the first patient in Australia has successfully received a kidney transplant after being treated with a new medication called Idefirix® (imlifidase).…
As reported on BioSpace, AstraZeneca has discontinued a pivotal Phase 3 trial evaluating its investigational bispecific antibody volrustomig in advanced non-small cell lung cancer (NSCLC) after an interim analysis indicated…
A recent study shared by The Lancet shows that a first-in-class investigational therapy targeting neurotrophin-3 (NT-3) significantly reduced pain and improved function in patients with knee osteoarthritis (OA), according to…
As reported on Fierce Biotech, Silence Therapeutics reported positive phase 2 findings for divesiran, an investigational small interfering RNA (siRNA) treatment for polycythemia vera (PV), a rare blood cancer marked…
As reported on The ASCO Post, perioperative treatment with enfortumab vedotin-ejfv plus pembrolizumab resulted in superior event-free survival, overall survival, and pathologic response rates compared with neoadjuvant cisplatin/gemcitabine in cisplatin-eligible…
As reported on Drugs, Eli Lilly has reported positive topline findings from two additional Phase 3 trials of retatrutide, its investigational triple hormone receptor agonist designed to target GIP, GLP-1,…
As reported on PharmaBiz, AstraZeneca has reached an important regulatory milestone in Europe after the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Trixeo…
As reported on Clinical Trials Arena, the US Food and Drug Administration (FDA) has released its final guidance on the clinical development of psychedelic therapies, providing drug developers with a…
Two of Intellia Therapeutics’ clinical trials that had been on hold since October 2025 have now been released by the FDA. The Agency initially issued the holds due to reports…
As covered by Fairfax Times, Novo Nordisk has reported encouraging long-term findings for its investigational hemophilia A therapy denecimig (Mim8), with interim results from the Phase 3 FRONTIER4 extension study…
As reported on BioSpace, BridgeBio Pharma has reported new findings suggesting that its transthyretin (TTR) stabilizer, Attruby (acoramidis), may help preserve kidney function in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM),…
New research from the 2026 American Society of Clinical Oncology (ASCO) annual meeting, and presented on Cure Today, highlights an encouraging new treatment on the horizon for advanced non-small cell…
What Happened? The healthcare company Grifols announced in a recent press release that it has enrolled and dosed the very first patient in a new Phase 3 clinical trial called…
Early Clinical Results Highlight Potential New Treatment Strategy As reported on STAT News, a novel investigational drug combination developed through a collaboration between Tango Therapeutics and Revolution Medicines has demonstrated…
As reported by PharmaBiz, Eli Lilly and Company has announced positive findings from its Phase 3 BRUIN CLL-322 trial evaluating pirtobrutinib (Jaypirca), a next-generation non-covalent Bruton tyrosine kinase (BTK) inhibitor,…
As reported on PharmaBiz, Sumitomo Pharma America (SMPA) presented new clinical and translational data spanning myelofibrosis (MF) and acute leukemia programs at the 2026 European Hematology Association Congress in Stockholm…
As reported on Yahoo News, a combination therapy involving nivolumab (Opdivo) from Bristol Myers Squibb and cabozantinib (Cabometyx) from Exelixis has demonstrated substantial clinical benefit in patients with previously untreated…
In a recent statement, CONNECTA Therapeutics, a biotechnology company focused on disorders of the central nervous system, has announced the start of its Phase IIa clinical trial for CTH120, a…
As reported on Medscape, global phase 3 clinical trial suggests that veligrotug, an investigational monoclonal antibody targeting the insulin-like growth factor‑1 receptor (IGF‑1R), may offer fast and lasting improvement for…
As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has approved a new adjuvant treatment option for adults with clear cell renal cell carcinoma (ccRCC) at elevated…
As reported on MedCity News, the U.S. Food and Drug Administration (FDA) has issued draft guidance encouraging the thoughtful use of Bayesian statistical approaches in clinical trials, marking a notable…
As reported on Becker's Hospital Review, the U.S. Food and Drug Administration’s launch of a real-time clinical trial model marks a notable shift in how oncology research is conducted and…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
